Responses
Late-Breaking Abstracts
Clinical Trials in Progress
955 CORE1: phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG)
Compose a Response to This Article
Other responses
No responses have been published for this article.